The proposed study is a phase 1, open label, single arm study to evaluate the safety and
antiretroviral activity of the combination of two long-acting broadly neutralizing
antibodies, 3BNC117-LS dosed once at 30 mg/kg and 10-1074-LS dosed once at 10 mg/kg, both
intravenously (IV) at week 0, plus an IL-15 superagonist complex, N-803, dosed at 6 mcg/kg,
subcutaneously (SC) at week 1 and then every 3 weeks for a total of 8 doses, in ART-treated
adults living with HIV during analytical treatment interruption.
Phase:
Phase 1
Details
Lead Sponsor:
Rockefeller University
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) Perelman School of Medicine University of Pennsylvania Weill Medical College of Cornell University